Observational studyRMD open2022

Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).

Jacques-Eric Gottenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.